Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

BACKGROUND: Enzyme replacement therapy is currently the only approved therapy for Fabry disease. From June 2009 on, viral contamination of Genzyme's production facility resulted in a worldwide shortage of agalsidase beta leading to involuntary dose reductions (approved dose 1 mg/kg/eow, reduced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smid, Bouwien E, Rombach, Saskia M, Aerts, Johannes MFG, Kuiper, Symen, Mirzaian, Mina, Overkleeft, Hermen S, Poorthuis, Ben JHM, Hollak, Carla EM, Groener, Johanna EM, Linthorst, Gabor E
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3219561/
https://ncbi.nlm.nih.gov/pubmed/22041095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-6-69
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados